The Great Pharma Brexit? An Endpoints News snap poll finds most life sciences insiders predicting a debacle for the industry
Perceptions matter, especially when opinions about the future are being formed in an industry that holds the key to growth where it’s wanted most. And right now the global biopharma business sees Brexit doing far more harm to biopharma in the UK than good.
By large margins.
Following up on a story we ran late last week on one industry poll regarding Brexit — at a time the UK’s rocky departure from the EU had blown into a full fledged political crisis — we decided it would be fun to run a snap survey of our own among readers and Twitter followers to get a broad look at the industry’s view of Brexit’s impact on drug development work and biotech creation — a key field for the island economy.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.